Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS Secretary could be a win for psychedelic drug developers.

Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.

Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions about what a second Trump administration could mean for biopharmaceutical IP and drug patents.

A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far, and what's likely to come in the year ahead.

Anne Zimmerman, editor-in-chief of the Columbia University online journal, Voices in Bioethics discusses her concerns over the use of GLP-1 weight loss drugs in the U.S.

Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.